-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
dasabuvir
![{PARAM:[Name]}({[CAS]})](https://resource.bocsci.com/structure/1132935-63-7.gif)
| Category | Hepatitis C Virus (HCV) |
| CAS | 1132935-63-7 |
| Description | Dasabuvir is an antiviral drug for the treatment of hepatitis C. It inhibits hepatitis C virus (HCV) non-nucleoside NS5B palm polymerase to suppress RNA replicase. Dasabuvir is commonly used in combination with ombitasvir/paritaprevir/ritonavir to effect on HCV type 1. |
Product Information
| Synonyms | ABT333; ABT-333; ABT 333, Dasabuvir. Trade names: Viekira Pak (with ombitasvir/paritaprevir/ritonavir tablets), Exviera; N-(6-(3-(tert-butyl)-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-2-methoxyphenyl)naphthalen-2-yl)methanesulfonamide |
| IUPAC Name | N-[6-[3-tert-butyl-5-(2,4-dioxopyrimidin-1-yl)-2-methoxyphenyl]naphthalen-2-yl]methanesulfonamide |
| Molecular Weight | 493.578 |
| Molecular Formula | C26H27N3O5S |
| Canonical SMILES | CC(C)(C)C1=C(C(=CC(=C1)N2C=CC(=O)NC2=O)C3=CC4=C(C=C3)C=C(C=C4)NS(=O)(=O)C)OC |
| InChI | InChI=1S/C26H27N3O5S/c1-26(2,3)22-15-20(29-11-10-23(30)27-25(29)31)14-21(24(22)34-4)18-7-6-17-13-19(28-35(5,32)33)9-8-16(17)12-18/h6-15,28H,1-5H3,(H,27,30,31) |
| InChIKey | NBRBXGKOEOGLOI-UHFFFAOYSA-N |
| Purity | 98.40% |
| Density | 1.3±0.1 g/cm3 |
| Solubility | In Vitro: DMSO : ≥ 46 mg/mL(93.20 mM) In Vivo: 1.Add each solvent one by one:10% DMSO >> 40%PEG300 >> 5%Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.07 mM); Clear solution 2.Add each solvent one by one:10% DMSO >> 90% (20%SBE-β-CDin saline) Solubility: ≥ 2.5 mg/mL (5.07 mM); Clear solution 3.Add each solvent one by one:10% DMSO >> 90%corn oil Solubility: ≥ 2.5 mg/mL (5.07 mM); Clear solution |
| Appearance | White to yellow (Solid) |
| Application | the treatment of hepatitis C |
| Storage | Powder: -20°C: 3 years 4°C: 2 years In solvent: -80°C: 6 months -20°C: 1 month |
| Complexity | 938 |
| Exact Mass | 493.16714214 |
| Index Of Refraction | 1.641 |
| In Vitro | Dasabuvir (ABT-333) is at least 7,000-fold more selective for HCV genotype 1 polymerase compared to human/mammalian polymerases. Dasabuvir (ABT-333) inhibits polymerase enzyme activity of genotype 1 laboratory strain enzymes (H77, BK, N, and Con1 strains), as well as enzymes produced from polymerase genes from HCV genotype 1-infected subjects, with IC50s ranging from 2.2 and 10.7 nM. Dasabuvir (ABT-333) inhibits HCV subgenomic replicon replication in cell culture assays with EC50 values of 7.7 and 1.8 nM for genotypes 1a (H77) and 1b (Con1), respectively. In the presence of 40% human plasma, the inhibition potency is reduced by a factor of 12 to 13, and the EC50s of HCV genotypes 1a (H77) and 1b (Con1) replicates are 99 and 21 nM, respectively. |
| PSA | 118.90000 |
| Target | IC50: 2.2-10.7 nM (NS5B polymerase) |
| XLogP3-AA | 4.3 |